Overview

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation